Form 4: GlycoMimetics Director Acquires Stock Options

Sentiment:

SEC Filing


Director Timothy R. Pearson of GlycoMimetics, Inc. reports acquisition of stock options.

Summary

  • On May 1, 2024, Timothy R. Pearson, a director of GlycoMimetics, Inc., filed a Form 4.
  • The form reports the acquisition of stock options.
  • Pearson acquired options to purchase 40,000 shares of GlycoMimetics common stock at an exercise price of $1.62.
  • The options vest on May 1, 2025, contingent upon continued service.
  • The options expire on April 30, 2034.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports the acquisition of stock options by a company director.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, regarding the company's securities. This allows the public to see how company insiders are investing in their own company.

Stakeholder Impact

  • The acquisition of stock options by a director could be viewed positively by shareholders, as it aligns the director's interests with the company's performance.

Key Dates

DateDescription
05/01/2024Date of transaction and filing of Form 4; acquisition of stock options.
05/01/2025Vesting date for the stock options, contingent upon continued service.
04/30/2034Expiration date of the stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.